ALS Clinical Trials in Houston

Showing 1-20 of 54 trials

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

NCT07023835

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

Zydus Therapeutics Inc.240 participantsStarted Sep 2025

La Jolla, California, United States • Orange, California, United States • San Francisco, California, United States +14 more locations

Active Not RecruitingPhase 2< 1 mile

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

NCT06643481

This is a multicenter, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early-stage ALS (within 2 years of ALS symptoms onset). The study comprises a core double-blind (DB) 40-week treatment period followed by an open label extension (OLE).

Amyotrophic Lateral Sclerosis (ALS)

Novartis Pharmaceuticals251 participantsStarted Oct 2024

La Jolla, California, United States • Loma Linda, California, United States • Los Angeles, California, United States +89 more locations

Page 1 of 3Next

Usnoflast Neuromuscular Investigation for Treatment Efficacy in Amyotrophic Lateral Sclerosis

A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)

ALS Trials in Other Cities

The Myelin Disorders Biorepository Project

A Study to Assess the Safety, Tolerability, and Effect on Disease Progression of BIIB105 in Participants With Amyotrophic Lateral Sclerosis (ALS) and Participants With the ALS Ataxin-2 (ATXN2) Genetic Mutation

Study to Assess the Effects of PTC857 Treatment in Participants With Amyotrophic Lateral Sclerosis ALS

Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension

Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral Palsy

Clinical Procedures to Support Research in ALS

PREVENT ALL ALS Study

ASSESS ALL ALS Study

A Second Intermediate-Size Expanded Access Protocol (EAP) for Pridopidine in People With Amyotrophic Lateral Sclerosis (Pridopidine EAP 2)

Intermediate Expanded Access Protocol CNMAu8.EAP04

Prospective Database Registry Study of Scoliosis in Children With Cerebral Palsy

Arimoclomol in Amyotropic Lateral Sclerosis

Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)

Phenotype, Genotype and Biomarkers 2

Intermuscular Coherence as a Biomarker for ALS

Long-Term Evaluation of BIIB067 (Tofersen)

Shared Decision Making to Improve Goals of Care in the ED

TJ-68 Clinical Trial in Patients With Amyotrophic Lateral Sclerosis (ALS) and Muscle Cramps

Other Conditions in Houston